Adagene Stock Performance
| ADAG Stock | USD 1.81 0.04 2.26% |
The firm shows a Beta (market volatility) of -0.96, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Adagene are expected to decrease slowly. On the other hand, during market turmoil, Adagene is expected to outperform it slightly. At this point, Adagene has a negative expected return of -0.15%. Please make sure to confirm Adagene's mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if Adagene performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Adagene has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
1 | ADAG Stock Rises Amid Biotech Sector Gains | 12/24/2024 |
2 | Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody ADG126 in AdvancedMetastatic Microsatellite-Stable Colorectal Cancer on January 25, 2025 | 01/14/2025 |
3 | Adagene to Announce Updated Data from Phase 1b2 Study of Muzastotug in Combination with KEYTRUDA in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium | 01/21/2025 |
4 | Adagene to present new ADG126 clinical data at ASCO-GI - MSN | 01/22/2025 |
5 | H.C. Wainwright lifts Adagene stock target to 8 on ASCO data - Investing.com | 01/27/2025 |
6 | Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 0757 am EST - Marketscreener.com | 01/31/2025 |
7 | Adagene Inc. Short Interest Update - MarketBeat | 02/13/2025 |
8 | Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug in ... | 02/27/2025 |
9 | Adagene to Present at Leerinks Global Healthcare Conference 2025 | 03/06/2025 |
10 | Adagene to Present at 11th Annual Immuno-Oncology 360 Summit | 03/13/2025 |
| Begin Period Cash Flow | 143.8 M |
Adagene |
Adagene Relative Risk vs. Return Landscape
If you would invest 204.00 in Adagene on December 18, 2024 and sell it today you would lose (23.00) from holding Adagene or give up 11.27% of portfolio value over 90 days. Adagene is currently does not generate positive expected returns and assumes 3.3423% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Adagene, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adagene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adagene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adagene, and traders can use it to determine the average amount a Adagene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0439
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADAG |
Estimated Market Risk
| 3.34 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Adagene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adagene by adding Adagene to a well-diversified portfolio.
Adagene Fundamentals Growth
Adagene Stock prices reflect investors' perceptions of the future prospects and financial health of Adagene, and Adagene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adagene Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (45.35) % | ||||
| Current Valuation | 3.54 M | ||||
| Shares Outstanding | 44.27 M | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 96.13 X | ||||
| Revenue | 18.11 M | ||||
| Gross Profit | 10.18 M | ||||
| EBITDA | (14.95 M) | ||||
| Net Income | (18.95 M) | ||||
| Cash And Equivalents | 168.04 M | ||||
| Cash Per Share | 3.87 X | ||||
| Total Debt | 22.31 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 3.10 X | ||||
| Book Value Per Share | 1.28 X | ||||
| Cash Flow From Operations | (28.45 M) | ||||
| Earnings Per Share | (0.72) X | ||||
| Market Capitalization | 108.46 M | ||||
| Total Asset | 115.73 M | ||||
| Retained Earnings | (277.75 M) | ||||
| Working Capital | 81.99 M | ||||
About Adagene Performance
By analyzing Adagene's fundamental ratios, stakeholders can gain valuable insights into Adagene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Adagene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Adagene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.31) | (0.29) |
Things to note about Adagene performance evaluation
Checking the ongoing alerts about Adagene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adagene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adagene generated a negative expected return over the last 90 days | |
| Adagene may become a speculative penny stock | |
| Adagene has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.11 M. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 10.18 M. | |
| Adagene currently holds about 168.04 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Adagene has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Adagene to Present at 11th Annual Immuno-Oncology 360 Summit |
- Analyzing Adagene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adagene's stock is overvalued or undervalued compared to its peers.
- Examining Adagene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adagene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adagene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adagene's stock. These opinions can provide insight into Adagene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Adagene Stock analysis
When running Adagene's price analysis, check to measure Adagene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adagene is operating at the current time. Most of Adagene's value examination focuses on studying past and present price action to predict the probability of Adagene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adagene's price. Additionally, you may evaluate how the addition of Adagene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |